BOCA RATON, FL - July 8, 2025 (NEWMEDIAWIRE) - Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB:VYCO), today announced that the publication of a new peer reviewed clinical paper on its NovaVision division’s NeuroEyeCoach training program. This important study provides further clinical data supporting its NeuroEyeCoach as a standard of care in saccadic training, resulting in significant improvement in visual search performance and a reduction in visual disability, and in particular its relevance to the growing global trend towards at-home digital health.
The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgery; and NovaVision®, a business in development which offers therapy programs to help patients recover from visual disorders after stroke or brain injury.
NeuroEyeCoach was validated in a 296 patient peer-reviewed clinical study published in Cortex, which demonstrated significant improvements in visual search. This study remains the largest published eye movement training study, with clinical results evidencing strong efficacy of NeuroEyeCoach, with 87% improvements in search time and 80% of patients making fewer errors. The study was led by University of Aberdeen, UK, and the University of Miami Miller School of Medicine, USA.
This new study, which follows on from the Cortex study, has been published by Springer May 2025 Experimental Brain Research. This study was done as a collaboration between the Neurorehabilitation unit of the Neuromotor and Cognitive Rehabilitation Research Centre, University of Verona, Italy, and NovaVision. Ethical approval was granted by the Psychology Ethics Committee, University of Aberdeen, UK. The study compared two patient groups who used NeuroEyeCoach; 95 consecutive patients who accessed the therapy at home and 31 consecutive patients who attended the clinic in Verona.
NeuroEyeCoach was designed and developed to be able to provide eye movement training for patients in both a clinic setting and in a home setting. Vision rehabilitation provisions vary across Europe and even in various states in the US, ranging from specialist care in clinical settings to home-based training or advice. There has been a significant drive to access digital technologies in home settings in parts of Europe and remotely accessed therapies are promoted in the US. NeuroEyeCoach was designed to provide low-cost delivery to allow wide access. The purpose of the study was to assess if there are meaningful differences in the benefit to and improvement in patients in a clinic setting compared to a home setting.
Study Conclusions
The study concluded that the NeuroEyeCoach “compensatory eye movement training is an effective tool for rehabilitation of vision loss when used in clinical settings or accessed remotely from home”.
NeuroEyeCoach led to improvements for home-based and clinic-based patients in both objective measures of visual function such as reduced visual search times, lower search errors, and faster completion of a cancellation task as well as reduced subjective reports of disability. No significant differences were identified between the effect of training on activities of daily living between the home-based and clinic-based groups.
About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB: VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared or registered medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.
Vycor Medical’s FDA-cleared ViewSite™ Brain Access System (VBAS) a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system has been approved and used in over 300 hospitals in the US and in numerous countries internationally. VBAS is protected by 46 issued and 11 pending patents and has been validated through over 40 peer-reviewed studies. These studies demonstrate that use of VBAS results in: less brain tissue damage; less invasive procedure; improved access and better visibility; and reduced operating and recovery time. For an overview of Vycor Medical’s VBAS see VBAS Video.
NovaVision provides a suite of clinically supported vision rehabilitation therapies aimed at helping patients recover from visual impairments caused by stroke or other brain injury. The Visual Restoration Therapy (VRT) is the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage, making it a unique and important option for patients seeking to regain lost visual capabilities. The complementary NeuroEyeCoach program, clinically supported by a 296-patient study (the largest to date in the neuro visual space), enables dramatic improvements in patients’ ability to detect objects in the visual field by training them to make better eye movements with improvement in over 80% of patients. The NovaVision therapies, while showing a positive impact on these patients’ lives, still require significant development to allow them to successfully address their market potential. For an overview of NovaVision see NovaVision Video.
For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
Investor Relations Contacts:
B2i Digital:
David Shapiro
Chief Executive Officer
B2i Digital, Inc.
https://b2idigital.com/
212.579.4844 Office
david@b2idigital.com
https://www.linkedin.com/in/davidshapironyc
https://www.linkedin.com/company/b2i-digital
https://x.com/b2idigital
https://www.facebook.com/b2idigital
https://www.instagram.com/b2i_digital
https://www.youtube.com/@b2idigital
https://stocktwits.com/B2iDigital
https://www.reddit.com/user/b2idigital/
https://www.pinterest.com/b2idigital/
https://www.tiktok.com/@b2idigital
https://www.threads.net/@b2i_digital
https://bsky.app/profile/b2idigital.bsky.social
Vycor Medical, Inc. Contacts:
951 Broken Sound Parkway, Suite 320
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com
LinkedIn: https://www.linkedin.com/in/vycor-medical-inc/
Instagram: https://www.instagram.com/vycormedical/
Facebook: https://www.facebook.com/Vycor.Nova/
Twitter/X: https://x.com/vycormedical
YouTube: https://www.youtube.com/@vycormedical6049
NovaVision, Inc:
(561) 558-2000
clientservices@novavision.com
LinkedIn: https://www.linkedin.com/company/novavisioninc
Facebook: https://www.facebook.com/novavisionusa/
Twitter/X https://x.com/NovaVision3
